Allergan Announces Conference Call to Discuss FDA Advisory Committee Meeting on Oral Tazarotene.IRVINE, Calif. -- Allergan, Inc. (NYSE NYSE See: New York Stock Exchange :AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) invites you to listen to Patricia S. Walker, M.D., Ph.D., Vice President, Clinical Research and Development, Skin Care Pharmaceuticals, Peter Kresel, Senior Vice President Global Regulatory Affairs, and Jim Hindman, Senior Vice President Treasury, Risk and Investor Relations Investor relations The process by which the corporation communicates with its investors. , discuss the clinical aspects of the Oral Tazarotene FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Advisory Committee Meeting held Monday, July 12, 2004. The call will take place Tuesday, July 13, 2004 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). The live Webcast can be accessed through the Allergan Website, www.allergan.com, beginning at 8:00 a.m. Eastern Time. A replay of the discussion will also be available from Tuesday, July 13 at 11:00 a.m. Eastern Time until Thursday, July 15 at 7:00 p.m. Eastern Time and can be accessed through www.allergan.com, 1-866-467-2554 for domestic locations, or 1-203-369-1450 for international locations. A passcode will not be required. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion